Corixa expects Bexxar advisory cmte. review
Executive Summary
Corixa expects to present Bexxar (tositumomab) to FDA's Oncologic Drug Advisory Committee before the end of the year. The committee has cancelled its Sept. 23 meeting date, but is tentatively scheduled to reconvene Dec. 17 and 18. Corixa requested the review in its appeal of a March 12 "complete review" letter for the non-Hodgkin's lymphoma therapy (1"The Pink Sheet" July 1, In Brief)...